Table 1 Clinical characteristics by cohort for samples used for algorithm training
From: Development and verification of the PAM50-based Prosigna breast cancer gene signature assay
| Characteristic | BC no AST | WashU | UNC | BC TAM |
|---|---|---|---|---|
| Median Follow Up (Years) | 11.9 | NA | NA | 12.1 |
| Patient Age | ||||
| Mean | 59.9 | 59.3 | 56.5 | 66.3 |
| Stdev | 13.8 | 15.2 | 15.9 | 9.6 |
| Premenopausal | ||||
| Yes | 81 | 0 | 0 | 10 |
| No | 214 | 0 | 0 | 219 |
| Unknown | 9 | 118 | 92 | 3 |
| ER Status | ||||
| Positive | 203 | 65 | 47 | 232 |
| Negative | 99 | 48 | 30 | 0 |
| Unknown | 2 | 5 | 15 | 0 |
| Node Status | ||||
| Positive | 18 | 57 | 41 | 0 |
| Negative | 276 | 58 | 35 | 232 |
| Unknown | 10 | 3 | 16 | 0 |
| HER2 Status | ||||
| Positive | 44 | 31 | 21 | 19 |
| Negative | 253 | 59 | 51 | 210 |
| Unknown | 7 | 28 | 20 | 3 |
| PR Status | ||||
| Positive | 138 | 50 | 34 | 130 |
| Negative | 139 | 63 | 38 | 86 |
| Unknown | 27 | 5 | 20 | 16 |
| Tumor Size | ||||
| ≤2 | 193 | 87 | 24 | 149 |
| >2 | 111 | 29 | 49 | 83 |
| Unknown | 0 | 2 | 19 | 0 |
| Grade | ||||
| 1 | 26 | 5 | 10 | 15 |
| 2 | 127 | 32 | 20 | 103 |
| 3 | 145 | 78 | 43 | 108 |
| Unknown | 6 | 3 | 19 | 6 |